FOLFOXIRI vs. Capecitabine + Radiotherapy for Locally Advanced Rectal Cancer: A Comparative Study
Preoperative radiation and chemotherapy are the standard treatment for locally advanced rectal cancer. The addition of oxaliplatin to capecitabine combined with radiotherapy does not improve local control and long-term survival. In the absence of effective measures of predicting chemosensitivity, there is considerable risk of using any two-drug regimen for neoadjuvant therapy. Simultaneous use of the three chemotherapeutic drugs may be able to reduce the likelihood of resistance to both dual drug regimen and single drug regimen. The purpose of this study is to compare the efficacy and safety of three chemotherapeutic regimen known as FOLFOXIRI (the drug 5-fluorouracil, oxaliplatin, Irinotecan) with standard radiotherapy combined with capecitabine in neoadjuvant therapy for locally advanced rectal cancer. The drugs in the FOLFOXIRI regimen are all FDA(Food and Drug Administration) approved and have been used routinely to treat patients with advanced colorectal cancer.
原文地址: https://www.cveoy.top/t/topic/fwmu 著作权归作者所有。请勿转载和采集!